Publications by authors named "M Jinnin"

To identify patients with infantile hemangioma (IH) in need of early-stage treatment in this multicenter, prospective, observational study, we investigated the potential of plasma cytokines as a clinically useful marker. Plasma samples were collected at three time points from 41 patients with infantile hemangioma: baseline (days 14-60 after delivery), visit 1 (days 61-150, the proliferative phase), and visit 2 (days 151-395, the involuting phase). With a twofold or more increase in tumor volume during the baseline-visit 1 period regarded as progression, progression was seen in 15 cases (36.

View Article and Find Full Text PDF

Aberrant immune responses to viral pathogens contribute to pathogenesis, but our understanding of pathological immune responses caused by viruses within the human virome, especially at a population scale, remains limited. We analyzed whole-genome sequencing datasets of 6,321 Japanese individuals, including patients with autoimmune diseases (psoriasis vulgaris, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and coronavirus disease 2019 (COVID-19), or healthy controls. We systematically quantified two constituents of the blood DNA virome, endogenous HHV-6 (eHHV-6) and anellovirus.

View Article and Find Full Text PDF

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis preceded by bronchial asthma or allergic sinusitis and accompanied by peripheral blood eosinophilia. Immunosuppressive drugs, such as cyclophosphamide in addition to high-dose glucocorticoids, are recommended for induction of remission in patients with severe EGPA. Although mepolizumab is widely recognized as remission induction therapy in non-fatal/non-organ disabling or relapsed/refractory EGPA, its efficacy and safety in induction of remission for severe cases have been ambiguous.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined whether a standard dose of bilastine (20 mg) is as effective as a double dose of second-generation H1-antihistamines for treating patients with refractory chronic spontaneous urticaria (CSU).
  • Conducted as a phase IV, multicenter trial, it involved 128 patients and measured treatment efficacy through the mean total symptom score (TSS) after 5-7 days of administration.
  • Results showed that bilastine was non-inferior in effectiveness to double-dose H1AH and had a similar safety profile, with no serious adverse effects reported in either treatment group.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates prognostic indicators in Japanese patients with early-stage systemic sclerosis (SSc) to predict disease progression, particularly focusing on those with diffuse cutaneous involvement and/or interstitial lung disease.
  • Researchers assessed clinical and laboratory parameters in a cohort of 115 patients followed for 4 years, analyzing correlations between baseline measurements and outcomes.
  • Key findings suggest that certain factors, such as finger-to-palm distance and the presence of anti-topoisomerase I antibodies, can help anticipate disease progression, but further research with larger samples is necessary for validation.
View Article and Find Full Text PDF